Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Effectiveness of anti-tumor necrosis factor agents in the treatment of rheumatoid arthritis: observational study.

D'Souza A, Meissner BL, Tang B, McKenzie RS, Piech CT.

Am Health Drug Benefits. 2010 Jul;3(4):266-73.

2.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

3.

Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study.

Schabert VF, Bruce B, Ferrufino CF, Globe DR, Harrison DJ, Lingala B, Fries JF.

Curr Med Res Opin. 2012 Apr;28(4):569-80. doi: 10.1185/03007995.2012.656844. Epub 2012 Mar 6.

PMID:
22236091
4.

Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.

Bonafede MM, Gandra SR, Fox KM, Wilson KL.

J Med Econ. 2012;15(4):635-43. doi: 10.3111/13696998.2012.667028. Epub 2012 Mar 1.

PMID:
22332705
5.

Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.

Ollendorf DA, Klingman D, Hazard E, Ray S.

Clin Ther. 2009 Apr;31(4):825-35. doi: 10.1016/j.clinthera.2009.04.002.

PMID:
19446156
6.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

7.

Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis.

Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R.

Pharmacotherapy. 2010 Apr;30(4):339-53. doi: 10.1592/phco.30.4.339. Review.

PMID:
20334454
8.

Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.

Carter CT, Changolkar AK, Scott McKenzie R.

J Med Econ. 2012;15(2):332-9. doi: 10.3111/13696998.2011.649325. Epub 2012 Jan 6.

PMID:
22168788
9.

Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.

Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW.

J Rheumatol. 2011 Jul;38(7):1273-81. doi: 10.3899/jrheum.101142. Epub 2011 May 15.

PMID:
21572150
10.

Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.

Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, Wassenberg S, Kapelle A, Listing J.

Arthritis Rheum. 2006 Nov;54(11):3399-407.

11.

Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis.

Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M.

Curr Med Res Opin. 2008 Aug;24(8):2229-40. doi: 10.1185/03007990802229548. Epub 2008 Jun 23.

PMID:
18577308
12.

Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice.

Ramírez-Herráiz E, Escudero-Vilaplana V, Alañón-Plaza E, Trovato-López N, Herranz-Alonso A, Morell-Baladrón A, Sanjurjo-Sáez M.

Clin Exp Rheumatol. 2013 Jul-Aug;31(4):559-65. Epub 2013 May 27.

PMID:
23710583
14.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

15.

The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study.

Finckh A, Simard JF, Duryea J, Liang MH, Huang J, Daneel S, Forster A, Gabay C, Guerne PA.

Arthritis Rheum. 2006 Jan;54(1):54-9.

16.

Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.

Saougou I, Markatseli TE, Papagoras C, Voulgari PV, Alamanos Y, Drosos AA.

Semin Arthritis Rheum. 2011 Apr;40(5):398-406. doi: 10.1016/j.semarthrit.2010.07.004. Epub 2010 Sep 16.

PMID:
20843542
17.

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.

Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Østergaard M; All Departments of Rheumatology in Denmark.

Arthritis Rheum. 2010 Jan;62(1):22-32. doi: 10.1002/art.27227.

18.

Influence of tumor necrosis factor α in rheumatoid arthritis.

Kulp W, Corzillus M, Greiner W, Pientka L, Siebert U, von der Schulenburg JM, Wasem J.

GMS Health Technol Assess. 2005 Dec 21;1:Doc12.

19.

Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.

Bonafede M, Fox KM, Watson C, Princic N, Gandra SR.

Adv Ther. 2012 Aug;29(8):664-74. doi: 10.1007/s12325-012-0037-5. Epub 2012 Aug 8.

PMID:
22886712
20.

Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis: a systematic review of cohort studies with focus on dose.

Eng G, Stoltenberg MB, Szkudlarek M, Bouchelouche PN, Christensen R, Bliddal H, Marie Bartels E.

Semin Arthritis Rheum. 2013 Oct;43(2):144-51. doi: 10.1016/j.semarthrit.2013.01.007. Epub 2013 Jul 6. Review.

PMID:
23838092
Items per page

Supplemental Content

Write to the Help Desk